24/7 BIOPHARMA - issue 1 / October 2024

CORDENPHARMA

CordenPharma’s 2024 investments and global platform approach to CDMO development and commercialisation support pharma innovators to address their drug lifecycle gaps and reach patients faster.

CordenPharma provides CDMO services that elevate pharma and biotech customers to support complex modalities across the drug development spectrum. By aligning our facilities and technology platforms to anticipate the challenges innovators often encounter as they work through development phases towards commercial markets and patients, CordenPharma offers bespoke end-to-end services designed to promote the rapid scale-up of pre-clinical, clinical and commercial manufacturing capabilities, and the latest technology to accelerate development of today’s most advanced large and small-molecule therapeutics. With our fully-integrated supply model as an overarching focus, CordenPharma has made recent, significant investments across all six technology platforms (Peptides, Oligonucleotides,

expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions designed and built according to the pharmaceutical industry’s most stringent quality and technical standards for short and long peptide manufacturing, including Biologics License Applications (BLA) requirements. The US expansion involves bringing additional Peptide capacity to our CordenPharma Colorado site with the planned construction of a new large-scale manufacturing facility and an additional increase in manufacturing trains in the existing facility.

Injectables, Lipids & Carbohydrates, Highly Potent & Oncology and Small Molecules).

On 16 July, 2024, we announced our largest strategic investment to date to grow our Peptide technology platform with a committed spend of ~€900m over the next three years. These transformational plans consist of two major

20

TWENTYFOURSEVENBIOPHARMA Issue 1 / October 2024